Article
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Blood - 21 May 2015
Daver Naval, Cortes Jorge, Ravandi Farhad, Patel Keyur P, Burger Jan A, Konopleva Marina, Kantarjian Hagop
Abstract excerpt
The advent of small molecule-based targeted therapy has improved the treatment of both acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a common theme. The most frequent mode of acquired resistance is the acquisition of point mutations in the kinase domain. FLT3 inhibitors have improved response rates in FLT3-mutated acute myeloid leukemia (AML). The occurrence of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.